Global Cardiac Resynchronization Therapy (CRT) Devices Industry

Global Cardiac Resynchronization Therapy (CRT) Devices Industry

  • September 2020 •
  • 126 pages •
  • Report ID: 5956227 •
  • Format: PDF
Global Cardiac Resynchronization Therapy (CRT) Devices Market to Reach $8.9 Billion by 2027

Amid the COVID-19 crisis, the global market for Cardiac Resynchronization Therapy (CRT) Devices estimated at US$5.7 Billion in the year 2020, is projected to reach a revised size of US$8.9 Billion by 2027, growing at aCAGR of 6.5% over the period 2020-2027. CRT-Defibrillator (CRT-D), one of the segments analyzed in the report, is projected to record 6.2% CAGR and reach US$6.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the CRT-Pacemaker (CRT-P) segment is readjusted to a revised 7.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.7 Billion, While China is Forecast to Grow at 6.1% CAGR

The Cardiac Resynchronization Therapy (CRT) Devices market in the U.S. is estimated at US$1.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2027 trailing a CAGR of 6.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6% and 5.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.We bring years of research experience to this 6th edition of our report. The 126-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,
  • Abbott Laboratories
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • LivaNova PLC
  • Medtronic PLC